Gilead Sciences (GILD) closed at $131.14 in the latest trading session, marking a +1.57% move from the prior day. This change ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Gilead Sciences Inc. stock reached an all-time high of 128.71 USD, marking a significant milestone for the biopharmaceutical company. According to InvestingPro data, the stock is trading just 0.99% ...

Gilead Sciences is undervalued, with a Buy rating and a DCF-based target price of $141, implying 13.4% upside. Click here to ...

Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased its price target for Gilead Sciences, Inc. (NASDAQ:GILD) from $131 to $140 ...

Is on Investors’ Radar Today Gilead Sciences (GILD) is drawing investor attention after recent trading left the stock with a 1-day return of about a 1% decline, alongside modest moves over the week ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Gilead Sciences (GILD) closed the most recent trading day at $118.30, moving -2.71% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.64%. Meanwhile, ...

Gilead's Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options begin trading today, for the May 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, ...